1.225.000 Stücke bei so einem Rotzkurs???
Ich wünschte hier würde mal was platzen...aber da seh ich weit und breit nix...
Ich wünschte hier würde mal was platzen...aber da seh ich weit und breit nix...
Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 44 45 46 47 48 50
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 44 45 46 47 48 50
STEM CELL- mit STEM CELL gute Kursgewine erzielen
Beiträge:
1.236
Zugriffe: 150.869 / Heute: 56
Zugriffe: 150.869 / Heute: 56
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +70,63%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +69,47%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +54,96%
Xtrackers MSCI USA Financials UCITS ETF 1D
Perf. 12M: +53,58%
Xtrackers MSCI Fintech Innovation UCITS ETF 1C
Perf. 12M: +51,68%
also ran an den Speck, bevor die Ammies den Braten riechen
Kann vielleicht jemand eine kurze Zusammenfassung erstellen was genau mit SCLL passiert ist und wie es weitergeht?
Meinen Dank vorab!
Meinen Dank vorab!
wann dieses Teil bei den Amies explodiert?!!
wär schon schön, wenn es mal zucken würde!
Ich glaub nicht mehr recht dran :-(
Ich glaub nicht mehr recht dran :-(
in meinem Depot sind sie zwar noch eingebucht, aber aber es gibt keinen Handelsplatz und somit keine Kurse...
es gibt Hoffnung für alle Aktionäre!
Warum?
Jesus Christus ist auch wieder Auferstanden von den Toten!
Warum?
Jesus Christus ist auch wieder Auferstanden von den Toten!
Kann mir jemand sagen, was dies bedeutet?
www.sec.gov/litigation/admin/2012/34-66240.pdf
www.sec.gov/litigation/admin/2012/34-66240.pdf
Angesichts des Vorangehenden (STEMS CELLS) hält die Kommission es für notwendig und passend für den Schutz der Investoren, die Sanktionen aufzuerlegen.
XXXTRADER
XXXTRADER
es wäre besser, die Aktionäre zu entschädigen, als dass die Firma von der entsprechenden Kommission Sanktionen auferlegt bekommt!
kann ev. jemand hier etwas genauer erklären was jetzt Sache ist ?
welche Sanktionen sollten das dann sein und was heißt das für uns ?
danke
welche Sanktionen sollten das dann sein und was heißt das für uns ?
danke
Zumindest Global Data will an der Firma noch verdienen. Was es da wöhl noch zu analysieren gibt? das die Firma delistet ist wissen wir auch so. 250€, wer gibt die wohl aus?
Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published by GlobalData on Mar 05, 2012 , 23 pages
§Description Table of Contents
Stem Cell Innovations, Inc. (SCI) is a privately held biotechnology company, based in the US. The company is engaged in the discovery and development of human cell based drugs. Its core technologies concentrate on developing, growing, and manipulating human cells in the laboratory using proprietary technology. The company is into the development of a broad array of human primary cell models, which can be used as powerful research tools to form the basis of therapeutic breakthroughs. SCI has established many human pluripotent stem cell lines fetal gonadal tissue using defined conditions, and the PluriCell lines are established directly onto tissue culture plastic without using feeder layers or conditioned medium. The company also has in vitro hepatocyte screening, kits, compositions, and services for compound toxicity testing, ACTIVTox and PREDICTIVTox in store. SCI is headquartered at Houston in Texas, the US.
Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.
Scope
Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description - A brief description of the company's operations.
Key Employees - A list of the key executives of the company.
Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors - A list of the key competitors of the company.
Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published by GlobalData on Mar 05, 2012 , 23 pages
§Description Table of Contents
Stem Cell Innovations, Inc. (SCI) is a privately held biotechnology company, based in the US. The company is engaged in the discovery and development of human cell based drugs. Its core technologies concentrate on developing, growing, and manipulating human cells in the laboratory using proprietary technology. The company is into the development of a broad array of human primary cell models, which can be used as powerful research tools to form the basis of therapeutic breakthroughs. SCI has established many human pluripotent stem cell lines fetal gonadal tissue using defined conditions, and the PluriCell lines are established directly onto tissue culture plastic without using feeder layers or conditioned medium. The company also has in vitro hepatocyte screening, kits, compositions, and services for compound toxicity testing, ACTIVTox and PREDICTIVTox in store. SCI is headquartered at Houston in Texas, the US.
Stem Cell Innovations, Inc. (SCLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.
Scope
Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description - A brief description of the company's operations.
Key Employees - A list of the key executives of the company.
Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors - A list of the key competitors of the company.
Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
aber vielleicht im Soge von MultiCell?
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Stem Cell Innovations Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
12 | 1.235 | STEM CELL- mit STEM CELL gute Kursgewine erzielen | brunneta | Bigbqq | 20.08.21 09:59 | |
| 15 | 1000% Chance mit US-Biotechnologie-Aktie | Investisseur | owausac | 25.08.11 19:56 | ||
| 8 | 494 | Achtung heute geht die Post ab | Friends | buddikatze | 26.01.10 13:13 |
